[HTML][HTML] High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19
LB Kreuziger, T Kwon, RS Kasthuri, L Wahid… - Research and Practice …, 2024 - Elsevier
Abstract Background The Accelerating COVID-19 Therapeutic Interventions and Vaccines-
4c (ACTIV-4c) trial investigated prophylactic apixaban for 30 days following hospitalization …
4c (ACTIV-4c) trial investigated prophylactic apixaban for 30 days following hospitalization …
High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19
L Baumann Kreuziger, T Kwon, RS Kasthuri, L Wahid… - 2024 - vtechworks.lib.vt.edu
Background: The Accelerating COVID-19 Therapeutic Interventions and Vaccines-4c (ACTIV-
4c) trial investigated prophylactic apixaban for 30 days following hospitalization for COVID …
4c) trial investigated prophylactic apixaban for 30 days following hospitalization for COVID …
Risk of Venous Thromboembolism in Hospitalized COVID-19 Patients Undergoing Thromboprophylaxis: Meta-analysis of Cohort Studies
Introduction: Preliminary evidence indicates that prophylactic-dosing thromboprophylaxis
may be inadequate to control the increased risk of venous thromboembolism (VTE) in …
may be inadequate to control the increased risk of venous thromboembolism (VTE) in …
Eligibility for Posthospitalization Venous Thromboembolism Prophylaxis in Hospitalized Patients With COVID‐19: A Retrospective Cohort Study
VM Vaughn, D Ratz, ES McLaughlin… - Journal of the …, 2022 - Am Heart Assoc
Background A recent randomized trial, the MICHELLE trial, demonstrated improved
posthospital outcomes with a 35‐day course of prophylactic rivaroxaban for patients …
posthospital outcomes with a 35‐day course of prophylactic rivaroxaban for patients …
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre …
E Ramacciotti, LB Agati, D Calderaro, VCR Aguiar… - The Lancet, 2022 - thelancet.com
Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …
Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID register
D Poli, E Antonucci, W Ageno, P Prandoni… - Internal and emergency …, 2022 - Springer
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and
extra-pulmonary complications; in particular, it may predispose to thromboembolic disease …
extra-pulmonary complications; in particular, it may predispose to thromboembolic disease …
Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization
Background: Patients hospitalized with COVID-19 have an increased incidence of
thromboembolism. The role of extended thromboprophylaxis after hospital discharge is …
thromboembolism. The role of extended thromboprophylaxis after hospital discharge is …
Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19
M Varasteh Kia, BD Lau, OP Owodunni… - Journal of Thrombosis …, 2021 - Springer
Introduction The incidence of venous thromboembolism (VTE) in patients hospitalized with
COVID-19 is higher than most other hospitalized patients. Nonadministration of …
COVID-19 is higher than most other hospitalized patients. Nonadministration of …
Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: a systematic review and meta-analysis
Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may
be inadequate to control the increased risk of venous thromboembolism (VTE) in patients …
be inadequate to control the increased risk of venous thromboembolism (VTE) in patients …
[HTML][HTML] Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study
KM Andersen, CS Joseph, HB Mehta, MB Streiff… - Research and Practice …, 2022 - Elsevier
Abstract Background and Objectives Current clinical guidelines recommend
thromboprophylaxis for adults hospitalized with coronavirus disease 2019 (COVID‐19), yet it …
thromboprophylaxis for adults hospitalized with coronavirus disease 2019 (COVID‐19), yet it …